SCHEMBL3201810

SCHEMBL3201810

Cc1ccc(S(=O)(=O)N2CCC(Oc3ccccc3F)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.63
FPR2 P25090 1/20 0.62
PROKR1 Q8TCW9 1/20 0.62
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 2/20 0.55
TP53 P04637 1/20 0.50
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.48
GAA P10253 2/20 0.48
USP2 O75604 1/20 0.48
POLB P06746 1/20 0.48
PKM P14618 1/20 0.48
PTGDR Q13258 2/20 0.48
HTR2A P28223 1/20 0.47
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210439 0.87 MEN1 (0.57) HTR2CMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3213292 0.86 MAPT (0.60) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL3222003 0.86 HTR2C (0.62) HTR2CMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3223665 0.85 MEN1 (0.55) HTR2CMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3222938 0.84 MEN1 (0.63) HTR2CFPR2PROKR1MEN1KMT2A
SCHEMBL3212962 0.84 PTGDR (0.57) MEN1KMT2ASMN1; SMN2MAPTTP53
SCHEMBL24590696 0.83 PTGDR (0.56) HTR2CMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3210436 0.83 MEN1 (0.53) HTR2CMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3224356 0.82 HSD11B1 (0.52) FPR2PROKR1MEN1KMT2ASMN1; SMN2
SCHEMBL3219582 0.82 SCD (0.53) MEN1KMT2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 HTR2C 1366/4885FPR2 3918/4885PROKR1 1585/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 HTR2C 806/4885FPR2 3342/4885PROKR1 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.